Information Provided By: 
Fly News Breaks for September 10, 2018
RARE
Sep 10, 2018 | 08:00 EDT
Morgan Stanley analyst Jeffrey Hung assumed coverage of Ultragenyx with an Equal Weight rating and $92 price target, stating that he believes expectations of strong launches for Mepsevii and Crysvita are largely priced into the shares. The company has a diverse pipeline, but most of it will take time to reach market, Hung added.
News For RARE From the Last 2 Days
